We are truly honored to have been named finalists for the prestigious 2024 European Lifestars Awards in the Women-Led … [Read more...] about Our CEO, Agnès Arbat, has achieved second place in the prestigious 2024 European Lifestars Awards, under the “Women-Led Business of the Year” category.
OXOLIFE has reached the final stage of the European Accelerator program
Exciting News! We are thrilled to announce that OXOLIFE has reached the final stage of the European Accelerator … [Read more...] about OXOLIFE has reached the final stage of the European Accelerator program
Watch our CEO Agnès Arbat talk to OptimumTV about fantastic Phase 2 results for our lead product OXO-001 and our plans for future
Agnès Arbat, explained in our last interview more details on our innovative solution for the treatment of female … [Read more...] about Watch our CEO Agnès Arbat talk to OptimumTV about fantastic Phase 2 results for our lead product OXO-001 and our plans for future
Our CEO Agnès Arbat has successfully made the finalist roster for the prestigious 2024 European Lifestars Awards in the Women-Led Business of the Year category
Winner will be announced in London during LSX Investival showcase, the kick off to Jefferies week on November … [Read more...] about Our CEO Agnès Arbat has successfully made the finalist roster for the prestigious 2024 European Lifestars Awards in the Women-Led Business of the Year category
A pill for infertility: Oxolife’s non-hormonal oral drug raises embryo implantation rate, pregnancy rates and live birth rate in women undergoing IVF and ICSI, data being presented at ESHRE shows
A pill for infertility: Oxolife’s non-hormonal oral drug raises embryo implantation rate, pregnancy rates and live birth … [Read more...] about A pill for infertility: Oxolife’s non-hormonal oral drug raises embryo implantation rate, pregnancy rates and live birth rate in women undergoing IVF and ICSI, data being presented at ESHRE shows
OXOART2, selected as one of the most exciting pieces of research presented at ESHRE 40th annual meeting celebrated in Amsterdam
Novel treatment improves embryo implantation and live birth rates in infertile women undergoing IVF and ICSI New … [Read more...] about OXOART2, selected as one of the most exciting pieces of research presented at ESHRE 40th annual meeting celebrated in Amsterdam
Oxolife will present the first OXO-001 results at the European Congress of Human Reproduction (ESHRE)
OXOLIFE is thrilled to announce that on Monday, July the 8th, our CEO, Agnès Arbat Arbat, will be presenting the … [Read more...] about Oxolife will present the first OXO-001 results at the European Congress of Human Reproduction (ESHRE)
Oxolife Appoints International Fertility Experts to its Scientific Advisory Board
Barcelona, Spain – 13th November 2023, Oxolife, the specialist biotech focused on enhancing embryo implantation in women … [Read more...] about Oxolife Appoints International Fertility Experts to its Scientific Advisory Board
OXO-001, for embryo implantation makes headlines in the Daily News!
Oxolife and its phase II asset OXO-001 for embryo implantation have been featured in the UK's highest circulated daily … [Read more...] about OXO-001, for embryo implantation makes headlines in the Daily News!
Oxolife in the radio
We are delighted to share the interview to our CEO Agnès Arbat on #Lideratges, Ariadna’s Belver Comin program, where … [Read more...] about Oxolife in the radio